Mersana Therapeutics Inc (MRSN)

NASDAQ
Currency in USD
Disclaimer
1.27
0.00(0.00%)
Closed
After Hours
1.270.00(0.00%)
Day's Range
1.251.29
52 wk Range
0.809.62
Prev. Close
1.27
Open
1.27
Day's Range
1.25-1.29
52 wk Range
0.8-9.62
Volume
1,091,810
Average Vol. (3m)
6,458,704
1-Year Change
-80.22%
Shares Outstanding
120,507,291
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
2.00
Upside +57.48%

People Also Watch

1.11
MYO
-1.33%
0.79
KSCP
+5.38%
0.870
NBSE
-7.47%
0.956
LVO
-1.42%

Mersana Therapeutics Inc Company Profile

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. The Company lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase I clinical trial evaluating UpRi in combination with carboplatin, and UP-NEXT, a Phase III clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Its pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Income Statement